(19) REPUBLIKA HRVATSKA
DRŽAVNI ZAVOD ZA
INTELEKTUALNO VLASNIŠTVO

(10) Identifikator dokumenta: **HR P20200274 T1**

HR P20200274 T1

(12) PRIJEVOD PATENTNIH ZAHTJEVA EUROPSKOG PATENTA

(51) MKP:
C07D 251/18 (2006.01)
C07D 401/04 (2006.01)
C07D 403/04 (2006.01)
C07D 405/14 (2006.01)
C07D 409/04 (2006.01)
C07D 417/04 (2006.01)
A61K 31/395 (2006.01)
A61P 35/00 (2006.01)

(46) Datum objave prijevoda patentnih zahtjeva: 29.05.2020.

(21) Broj predmeta: P20200274T

(22) Datum podnošenja zahtjeva u HR: 18.02.2020.

(86) Broj međunarodne prijave: PCT/CN2014081957
Datum podnošenja međunarodne prijave: 10.07.2014.

(96) Broj europske prijave patenta: EP 14822106.2
Datum podnošenja europske prijave patenta: 10.07.2014.

(87) Broj međunarodne objave: WO 2015003640
Datum međunarodne objave: 15.01.2015.

(97) Broj objave europske prijave patenta: EP 3019483 A1
Datum objave europske prijave patenta: 18.05.2016.

(97) Broj objave europskog patenta: EP 3019483 B1
Datum objave europskog patenta: 20.11.2019.

(31) Broj prve prijave: PCT/CN2013/079200 (32) Datum podnošenja prve prijave: 11.07.2013.
(33) Država ili organizacija podnošenja prve prijave: WO

(73) Nositelj patenta: **Agios Pharmaceuticals, Inc., 38 Sidney Street, Cambridge, MA 02139, US**
(72) Izumitelji: **Zenon D. Konteatis, 137 Southern Boulevard, Chatham, NJ 07928, US**
Janeta Popovici-Muller, 12 Clarke Farm Road, Windham, NH 03087, US
Jeremy M. Travins, 59 Flagg Road, Southborough, MA 01772, US
Robert Zahler, 5 East Welling Avenue, Pennington, NJ 08534, US
Zhenwei Cai, 33 Autumn Lane, Skillman, NJ 08558, US
Ding Zhou, 52 Yishashi Garden, 188 Chunjiu Road, Shanghai 201612, CN
(74) Zastupnik: ZMP IP d.o.o., 10000 Zagreb, HR

(54) Naziv izuma: **TERAPEUTSKI AKTIVNI SPOJEVI I POSTUPCI NJIHOVE UPORABE**

HR P20200274 T1

PATENTNI ZAHTJEVI

1. Spoj koji ima formulu Ia ili njegova farmaceutski prihvatljiva sol ili hidrat, naznačen time što:



(Ia),

prsten A je izabran od fenila, pirazolila, oksazolila, izoksazolila, piridinila, pirimidinila, pirazinila i tiazolila, pri čemu je prsten A izborno supstituiran sa do dva supstituenta nezavisno izabrana od halo, -C_1-C_4 alkila, -C_1-C_4 haloalkila, -C_1-C_4 hidroksialkila, -NH-S(O)$_2$-(C_1-C_4 alkil), -S(O)$_2$NH(C_1-C_4 alkil), -CN, -S(O)$_2$-(C_1-C_4 alkil), C_1-C_4 alkoksi, -NH(C_1-C_4 alkil), -OH, -OCF_3, -CN, -NH_2, -C(O)NH_2, -C(O)NH(C_1-C_4 alkil), -C(O)-N(C_1-C_4 alkil)$_2$ i ciklopropila izborno supstituiranog sa OH;

R^1, R^3, R^4 i R^6 su svaki nezavisno izabrani od vodika, C_1-C_4 alkila, C_1-C_4 haloalkila, -O-C_1-C_4 alkila i CN, pri čemu je svaka navedena alkil grupa od R^1, R^3, R^4, i R^6 nezavisno izborno supstituirana sa -OH, -NH_2, -CN, -O-C_1-C_4 alkil, -NH(C_1-C_4 alkil) ili -N(C_1-C_4 alkil)$_2$;

R^2 i R^5 su svaki nezavisno izabrani od: -(C_1-C_6 alkil), -(C_1-C_6 alkil)-C(O)-NH_2, -(C_1-C_6 alkil)-CO_2H, -(C_2-C_6 alkenil ili alkinil), -(C_1-C_6 alkilen)-O-(C_1-C_6 alkil), -(C_0-C_6 alkilen)-C(O)N(R^6)-(C_1-C_6 alkil) i -(C_0-C_6 alkilen)-C(O)-(C_1-C_6 alkil) gdje: svaka alkil ili alkilen grupa prisutna u R^2 i R^5 je izborno supstituirana s jednim ili više -OH, -O(C_1-C_4 alkil), -CO_2H ili halo;

svaka terminalna metil grupa prisutna u R^2 i R^5 je izborno zamijenjena sa -CH_2OH, CF_3, -CH_2F, -CH_2Cl, C(O)CH_3, C(O)CF_3, CN ili CO_2H;

R^7 i R^8 su svaki nezavisno izabrani od vodika i C_1-C_6 alkila; gdje

R^1 i R^2 su izborno uzeti zajedno tako da formiraju karbociklil ili heterociklil od kojih je bilo koji izborno supstituiran sa do 3 supstituenta nezavisno izabrana od halo, npr., fluoro, C_1-C_4 alkila, C_1-C_4 haloalkila, C_1-C_4 alkoksi, -CN, =O, -OH, arila, heteroarila, -SO_2C_1-C_4 alkila, -CO_2C_1-C_4 alkila, -C(O)arila i -C(O)C_1-C_4 alkila; ili

R^4 i R^5 su izborno uzeti zajedno tako da formiraju karbociklil ili heterociklil od kojih je bilo koji izborno supstituiran sa do 3 supstituenta nezavisno izabrana od halo, npr., fluoro, C_1-C_4 alkila, C_1-C_4 haloalkila, C_1-C_4 alkoksi, -CN, =O, -OH, arila, heteroarila, -SO_2C_1-C_4 alkila, -CO_2C_1-C_4 alkila, -C(O)arila i -C(O)C_1-C_4 alkila; gdje:

(i) kada je A jednak piridil izborno supstituiran kao što je opisano u prethodnom tekstu, tada (A) N(R^7)C(R^4)(R^5)(R^6) i N(R^8)C(R^1)(R^2)(R^3) nisu oba NHCH_2CH_2OH, ili NH-cikloheksil, i (B) kada je N(R^7)C(R^4)(R^5)(R^6) jednak N$HC(CH_3)_3$, tada N(R^8)C(R^1)(R^2)(R^3) nije NH-CH_2CH_3;

(ii) kada je A jednak pirazolil, oksazolil, izoksazolil, piridinil, pirimidinil, pirazinil ili tiazolil izborno supstituiran kao što je opisan u prethodnom tekstu, tada N(R^7)C(R^4)(R^5)(R^6) i N(R^8)C(R^1)(R^2)(R^3) nisu oba N(CH_2CH_3)$_2$, NHCH_2CH_2-i-propil ili N$HCH_2CH(CH_3)_2$;

(iii) kada je A jednak 1-pirazolil izborno supstituiran kao što je opisano u prethodnom tekstu, tada ni N(R^7)C(R^4)(R^5)(R^6) ni N(R^8)C(R^1)(R^2)(R^3) nisu NH-izopropil, NHCH_2CH_3, ili N(CH_2CH_3)$_2$,

(iv) kada je A jednako fenil izborno supstituiran kao što je opisano u prethodnom tekstu, tada N(R^7)C(R^4)(R^5)(R^6) nije isti kao N(R^8)C(R^1)(R^2)(R^3),

(v) spoj nije: N^2-izopropil-6-fenil-N^4-(tetrahidro-2H-piran-4-il)-1,3,5-triazin-2,4-diamin.

2. Spoj ili njegova farmaceutski prihvatljiva sol ili hidrat prema patentnom zahtjevu 1, naznačeno time što prsten A je izborno supstituiran sa do dva supstituenta nezavisno izabrana od halo, -C_1-C_4 alkila, -C_1-C_4 haloalkila, -C_1-C_4 hidroksialkila, -NH-S(O)$_2$-(C_1-C_4 alkil), -S(O)$_2$NH(C_1-C_4 alkil), -CN, -S(O)$_2$-(C_1-C_4 alkil), C_1-C_4 alkoksi, -NH(C_1-C_4 alkil), -OH, -CN i -NH_2.

3. Spoj ili njegova farmaceutski prihvatljiva sol ili hidrat prema patentnom zahtjevu 1, naznačen time što:

R^1, R^3, R^4 i R^6 su svaki nezavisno izabrani od vodika, C_1-C_4 alkila, C_1-C_4 haloalkila, -O-C_1-C_4 alkila i CN, pri čemu je svaka navedena alkil grupa od R^1, R^3, R^4 i R^6 nezavisno izborno supstituirana sa -OH, -NH_2, -CN, -O-C_1-C_4 alkilom, -NH(C_1-C_4 alkil) ili -N(C_1-C_4 alkil)$_2$;

R^2 i R^5 su svaki nezavisno izabrani od: -(C_1-C_6 alkil), -(C_1-C_6 alkil)-C(O)-NH_2, -(C_1-C_6 alkil)-CO_2H, -(C_2-C_6 alkenil ili alkinil), -(C_1-C_6 alkilen)-O-(C_1-C_6 alkil), -(C_0-C_6 alkilen)-C(O)N(R^6)-(C_1-C_6 alkil) i -(C_0-C_6 alkilen)-C(O)-(C_1-C_6 alkil), gdje:

bilo koja alkil ili alkilen grupa prisutna u R^2 i R^5 je izborno supstituirana jednim ili više -OH, -O(C_1-C_4 alkil), -CO_2H ili halo;

bilo koja terminalna grupa prisutna u R^2 i R^5 je izborno zamijenjena sa -CH_2OH, CF_3, -CH_2F, -CH_2Cl,C(O)CH_3, C(O)CF_3, CN ili CO_2H.

4. Spoj ili njegova farmaceutski prihvatljiva sol ili hidrat prema patentnom zahtjevu 1, naznačeno time što prsten A je piridinil izborno supstituiran sa halo ili -C_1-C_4 haloalkil.
5. Spoj ili njegova farmaceutski prihvatljiva sol ili hidrat prema patentnom zahtjevu 1, naznačen time što oba R^7 i R^8 su H.
6. Spoj koji ima formulu B, ili njegova farmaceutski prihvatljiva sol ili hidrat naznačen time što:



(B),

X je N, CH ili C-halo;
X^a je N ili C-R^{9a}, uz uvjet kada je jedan X^a jednak N, tada su druga dva X^a oba jednaki C-R^{9a};
R^9 je halo, -C_1-C_4 alkil, -C_1-C_4 haloalkil, -C_1-C_4 hidroksialkil, -NH-$S(O)_2$-(C_1-C_4 alkil), -$S(O)_2$NH(C_1-C_4 alkil), -CN, -$S(O)_2$-(C_1-C_4 alkil), C_1-C_4 alkoksi, -NH(C_1-C_4 alkil), -N(C_1-C_4 alkil)$_2$, -OH, -OCF_3, -CN, -NH_2, -$C(O)NH_2$, -C(O)NH(C_1-C_4 alkil), -C(O)-N(C_1-C_4 alkil)$_2$, -(C_1-C_6 alkilen)-O-(C_1-C_6 alkil), aril i ciklopropil izborno supstituiran sa OH;
svaki R^{9a} je nezavisno izabran od vodika, halo, -C_1-C_4 alkila, -C_1-C_4 haloalkila, -C_1-C_4 hidroksialkila, -NH-$S(O)_2$-(C_1-C_4 alkil), -$S(O)_2$NH(C_1-C_4 alkil), -CN, -$S(O)_2$-(C_1-C_4 alkil), C_1-C_4 alkoksi, -NH(C_1-C_4 alkil), -N(C_1-C_4 alkil)$_2$, -OH, -OCF_3, -CN, -NH_2, -$C(O)NH_2$,-C(O)NH(C_1-C_4 alkil), -C(O)-N(C_1-C_4 alkil)$_2$, -(C_1-C_6 alkilen)-O-(C_1-C_6 alkil), aril i ciklopropila izborno supstituiranog sa OH;
R^1, R^3, R^4 i R^6 su svaki nezavisno izabrani od vodika, C_1-C_4 alkila, C_1-C_4 haloalkila, -O-C_1-C_4 alkila i CN, pri čemu je svaka navedena alkil grupa od R^1, R^3, R^4 i R^6 nezavisno izborno supstituirana sa -OH, -NH_2, -CN, -O-C_1-C_4 alkil, -NH(C_1-C_4 alkil) ili -N(C_1-C_4 alkil)$_2$;
R^2 i R^5 su svaki nezavisno izabrani od: -(C_1-C_6 alkil), -(C_1-C_6 alkil)-C(O)-NH_2, -(C_1-C_6 alkil)-CO_2H, -(C_2-C_6 alkenil ili alkinil), -(C_1-C_6 alkilen)-O-(C_1-C_6 alkil), -(C_0-C_6 alkilen)-C(O)N(R^6)-(C_1-C_6 alkil), -(C_0-C_6 alkilen)-Q, -(C_0-C_6 alkilen)-C(O)-(C_1-C_6 alkil) i -(C_0-C_6 alkilen)-C(O)-(C_0-C_6 alkilen)-Q, gdje:
bilo koja alkil ili alkilen grupa prisutna u R^2 i R^5 je izborno supstituirana jednim ili više -OH, -O(C_1-C_4 alkil), -CO_2H ili halo;
bilo koja terminalna metil grupa prisutna u R^2 i R^5 je izborno zamijenjena sa -CH_2OH, CF_3, -CH_2F, -CH_2Cl, C(O)CH_3, C(O)CF_3, CN ili CO_2H;
R^7 i R^8 su svaki nezavisno izabrani od vodika i C_1-C_6 alkila; i
Q je izabran od arila, heteroarila, karbociklila i heterociklila, od kojih je bilo koji izborno supstituiran; gdje
R^1 i R^3 su izborno uzeti zajedno sa atomom ugljika za koji su vezani tako da formiraju C(=O); ili
R^4 i R^6 su izborno uzeti zajedno sa atomom ugljika za koji su vezani tako da formiraju C(=O); ili
R^1 i R^2 su izborno uzeti zajedno tako da formiraju izborno supstituiran karbociklil ili izborno supstituiran i heterociklil; ili
R^4 i R^5 su izborno uzeti zajedno tako da formiraju izborno supstituiran i karbociklil ili izborno supstituiran heterociklil; pri čemu spoj nije izabran iz grupe koju čine:
(1) 4,6-Pirimidindiamin, 2-(6-metil-2-piridinil)-N^4,N^6-dipropil-;
(2) 4,6-Pirimidindiamin, N^4-etil-2-(6-metil-2-piridinil)-N^6-propil-; i
(3) 4,6-Pirimidindiamin, N^4,N^4-dietil-2-(6-metil-2-piridinil)-N^6-propil-.
7. Spoj koji ima formulu C, ili njegova farmaceutski prihvatljiva sol ili hidrat, naznačen time što:



(C),

X je N, CH ili C-halo;

svaki X^b je nezavisno N-R^{9b}, O, S, C-H ili C-R^{9c}, uz uvjet da najmanje jedan X^b je C-R^{9c}, i kada je jedan X^b jednak C-H ili C-R^{9c} i drugi je C-R^{9c} tada je X^c jednak N, i kada je jedan X^b jednak N-R^{9b}, O ili S, tada je X^c jednak C;

R^{9b} je vodik ili -C_1-C_4 alkil;

R^{9c} je halo, -C_1-C_4 alkil, -C_1-C_4 haloalkil, -C_1-C_4 hidroksialkil, -NH-S(O)$_2$-(C_1-C_4 alkil), -S(O)$_2$NH(C_1-C_4 alkil), -CN, -S(O)$_2$-(C_1-C_4 alkil), C_1-C_4 alkoksi, -NH(C_1-C_4 alkil),-N(C_1-C_4 alkil)$_2$, -OH, -OCF_3, -CN, -NH_2, -C(O)NH_2, -C(O)NH(C_1-C_4 alkil), -C(O)-N(C_1-C_4 alkil)$_2$, -(C_1-C_6 alkilen)-O-(C_1-C_6 alkil), aril i ciklopropil izborno supstituiran sa OH; R^1, R^3, R^4 i R^6 su svaki nezavisno izabrani od vodika, C_1-C_4 alkila, C_1-C_4 haloalkila, -O-C_1-C_4 alkila i CN, pri čemu je svaka navedena alkil grupa od R^1, R^3, R^4 i R^6 nezavisno izborno supstituirana sa -OH, -NH_2, -CN, -O-C_1-C_4 alkil, -NH(C_1-C_4 alkil) ili -N(C_1-C_4 alkil)$_2$;

R^2 i R^5 su svaki nezavisno izabrani od: -(C_1-C_6 alkil), -(C_1-C_6 alkil)-C(O)-NH_2, -(C_1-C_6 alkil)-CO_2H, -(C_0-C_6 alkilen)-Q, -(C_0-C_6 alkilen)-C(O)-(C_1-C_6 alkil), -(C_0-C_6 alkilen)-C(O)-(C_0-C_6 alkilen)-Q, gdje:

bilo koja alkil ili alkilen grupa prisutna u R^2 i R^5 je izborno supstituirana sa jednim ili više -OH, -O(C_1-C_4 alkil), -CO_2H ili halo;

bilo koja terminalna metil grupa prisutna u R^2 i R^5 je izborno zamijenjena sa -CH_2OH, CF_3, -CH_2F, -CH_2Cl, C(O)CH_3, C(O)CF_3, CN ili CO_2H;

R^7 i R^8 su svaki nezavisno izabrani od vodika i C_1-C_6 alkila; i

Q je izabran od arila, heteroarila, karbociklila i heterociklila, od kojih je bilo koji izborno supstituiran ; gdje

R^1 i R^3 su izborno uzeti zajedno sa atomom ugljika za koji su vezani tako da formiraju C(=O); ili

R^4 i R^6 su izborno uzeti zajedno sa atomom ugljika za koji su vezani tako da formiraju C(=O); ili

R^1 i R^2 su izborno uzeti zajedno tako da formiraju izborno supstituiran karbociklil ili izborno supstituiran heterociklil; ili

R^4 i R^5 su izborno uzeti zajedno tako da formiraju izborno supstituiran i karbociklil ili izborno supstituiran i heterociklil; gdje:

(i) kada je X jednako CH i

je izborno supstituiran 1-imidazolil, izborno supstituiran i 1-pirolil ili izborno supstituiran i 1-pirazolil, tada ni N(R^7)C(R^4)(R^5)(R^6) ni N(R^8)C(R^1)(R^2)(R^3) nije NH(CH_2)$_7CH_3$, ili $NHCH_2CH_2OH$; i

(ii) kada su X i Xc oba jednaki N, tada ni N(R^7)C(R^4)(R^5)(R^6) ni N(R^8)C(R^1)(R^2)(R^3) nije N(CH_2CH_3)$_2$.

8. Spoj ili njegova farmaceutski prihvatljiva sol ili hidrat prema patentnom zahtjevu 7 naznačeno time što:

a) R^{9c} je halo, -OH, CN, -NH_2, -O-C_1-C_4 alkil, -NH(C_1-C_4 alkil), -N(C_1-C_4 alkil)$_2$, -C_1-C_4 alkil, -C_1-C_4 haloalkil i -(C_1-C_6 alkilen)-O-(C_1-C_6 alkil);

R^1 i R^4 su svaki vodik ;

R^3 i R^6 su svaki nezavisno izabrani od C_1-C_4 alkila, C_1-C_4 haloalkila, -O-C_1-C_4 alkila i CN; i

R^2 i R^5 su svaki -(C_1-C_6 alkil), gdje:

alkil grupa prisutna u R^2 i R^5 je izborno supstituirana sa jednim ili više -OH, -O(C_1-C_4 alkil), -CO_2H, ili halo; i bilo koja terminalna metil grupa prisutna u R^2 i R^5 je izborno zamijenjen sa -CH_2OH, CF_3, -CH_2F, -CH_2Cl, C(O)CH_3, C(O)CF_3, CN, ili CO_2H; ili

b) R^1 i R^4 su svaki nezavisno izabrani od C_1-C_4 alkila i C_1-C_4 haloalkila, i R^2 i R^5 su svaki -(C_1-C_6 alkil).

9. Spoj ili njegova farmaceutski prihvatljiva sol ili hidrat prema patentnom zahtjevu 1, naznačeno time što R^3 i R^6 su oba vodik , R^1 i R^4 su svaki nezavisno izabrani od C_1-C_4 alkila i C_1-C_4 haloalkila, i R^2 i R^5 su svaki -(C_1-C_6 alkil).

10. Spoj formule (Ig) ili njegova farmaceutski prihvatljiva sol ili hidrat, naznačeno time što:



(Ig),

prsten A je izborno supstituiran 5-6 –člani monocikličan aril ili monocikličan heteroaril;

R^3 i R^6 su oba vodik ;

R^1 i R^4 su svaki nezavisno izabrani od C_1-C_4 alkila i C_1-C_4 haloalkila; i

R^2 i R^5 su svaki -(C_1-C_6 alkil); ili

R^1 i R^2 su izborno uzeti zajedno tako da formiraju izborno supstituiran i monocikličan karbociklil; ili
R^4 i R^5 su izborno uzeti zajedno tako da formiraju izborno supstituiran monocikličan karbociklil;
gdje:

(i) prsten A nije izborno supstituiran triazolil, ili 3,5-dimetil-1H-pirazol-1-il,

(ii) kada su R^1 i R^2 izborno uzeti zajedno tako da formiraju nesupstituiran i cikloheksil, i R^4 i R^5 su izborno uzeti zajedno tako da formiraju nesupstituiran i cikloheksil, tada A nije disupstituiran 1-pirazolil ili nesupstituiran fenil;

(iii) spoj nije izabran iz grupe koju čine:

(1) 6-(1H-imidazol-1-il)-N^2,N^4-bis(1-metiletil)-1,3,5-Triazin-2,4-diamin;

(2) N^2,N^4-bis(1-metilpropil)-6-fenil-1,3,5-Triazin-2,4-diamin; ili

(3) 1,3,5-triazin-2,4-diamin, 6-(4-hloro-3,5-dimetil-1H-pirazol-1-il)-N^2,N^4-bis(1-metiletil)-.

11. Spoj prema patentnom zahtjevu 10 ili njegova farmaceutski prihvatljiva sol ili hidrat, naznačen time što A je piridinil izborno supstituiran sa halo ili -C_1-C_4 haloalkilom.
12. Spoj ili njegova farmaceutski prihvatljiva sol ili hidrat, izabran iz grupe koja se sastoji od:

1	
2	
3	
4	
5	
6	
7	

8	
9	
10	
11	
12	
13	
14	

15	 hiralno
16	 hiralno
17	 hiralno
18	 hiralno
19	 hiralno
31	
32	

33	
34	
35	
36	
37	
38	
39	

40	
41	
42	 hiralno
43	 hiralno
44	
45	 hiralno
46	 hiralno

47	 hiralno
48	 hiralno
50	 hiralno
51	 hiralno
52	
53	
54	

55	
56	
57	 hiralno
58	 hiralno
59	
60	 hiralno
61	 hiralno

63	 hiralno
64	 hiralno
65	 hiralno
66	 hiralno
67	 hiralno
69	
72	

73	
74	
75	
76	
77	
78	

79	
80	
81	
82	
86	
87	

88	
89	
90	
91	
92	
93	

94	
95	
96	
100	
101	
102	
103	

104	
105	
110	
111	
113	
114	

118	
121	
126	
128	
129	
130	

131	
135	
136	
138	
141	
142	

143	
144	
145	
146	
147	
148	

149	
150	
152	
155	
156	
157	
160	

161	
166	
170	
176	
180	
182	
183	

184	
186	
187	
188	
191	
193	

194	
196	
198	
199	
203	
205	

208	
209	
212	
214	
216	
218	
219	

222	
223	
224	
225	
227	
228	
230	

233	
234	
237	
240	
241	
249	
251	

252	
255	
256	
258	
262	
263	

264	
265	
266	
268	
269	
270	
271	

272	
273	
274	
275	
276	
277	
278	

279	
281	
282	
283	
284	
285	

286	
287	
290	
292	
293	
294	
295	

296	
297	
300	
301	
302	
303	
304	

305	
306	
307	
308	
309	
310	
311	

312	
314	
315	
317	
318	
319	
320	

321	
322	
323	
324	
326	
327	
328	

329	
330	
331	
332	
333	
334	
335	

339	
344	
345	
346	
354	
357	

363	
368	
370	
374	
386	
395	

399	
402	
403	
404	
406	
408	

409	
410	
411	
412	
414	
415	

416	
417	
418	
419	
420	
421	

422	
423	
424	

13. Spoj prema patentnom zahtjevu 12 ili njegova farmaceutski prihvatljiva sol ili hidrat, koji ima strukturu:



14. Spoj prema patentnom zahtjevu 12 ili njegova farmaceutski prihvatljiva sol ili hidrat, koji ima strukturu:



15. Spoj prema patentnom zahtjevu 12 ili njegova farmaceutski prihvatljiva sol ili hidrat, koji ima strukturu:



16. Spoj prema patentnom zahtjevu 12 ili njegova farmaceutski prihvatljiva sol ili hidrat, koji ima strukturu:



17. Spoj prema patentnom zahtjevu 12 ili njegova farmaceutski prihvatljiva sol ili hidrat, koji ima strukturu:



18. Spoj prema patentnom zahtjevu 12 ili njegova farmaceutski prihvatljiva sol ili hidrat, koji ima strukturu:



19. Spoj prema patentnom zahtjevu 12 ili njegova farmaceutski prihvatljiva sol ili hidrat, koji ima strukturu:



20. Spoj prema patentnom zahtjevu 12 ili njegova farmaceutski prihvatljiva sol ili hidrat, koji ima strukturu:



21. Spoj prema patentnom zahtjevu 12 ili njegova farmaceutski prihvatljiva sol ili hidrat, koji ima strukturu:



22. Spoj prema patentnom zahtjevu 12 ili njegova farmaceutski prihvatljiva sol ili hidrat, koji ima strukturu:



23. Farmaceutska kompozicija koja sadrži spoj ili njegovu farmaceutski prihvatljivu sol ili hidrat prema bilo kojem od patentnih zahtjeva 1 do 9 ili 11 do 22, i farmaceutski prihvatljiv nosač.
24. Farmaceutska kompozicija koja sadrži spoj koji ima formulu Ig ili njegovu farmaceutski prihvatljivu sol ili hidrat:



(Ig),

gdje

prsten A je izborno supstituiran 5-6 –člani monocikličan aril ili monocikličan heteroaril;
R^3 i R^6 su oba vodik ;
R^1 i R^4 su svaki nezavisno izabrani od C_1-C_4 alkila i C_1-C_4 haloalkila; i
R^2 i R^5 su svaki -(C_1-C_6 alkil); ili
R^1 i R^2 su izborno uzeti zajedno tako da formiraju izborno supstituiran monocikličan karbociklil; ili
R^4 i R^5 su izborno uzeti zajedno tako da formiraju izborno supstituiran monocikličan karbociklil;
gdje:
(i) prsten A nije izborno supstituiran triazolil ili 3,5-dimetil-1H-pirazol-1-il,
(ii) kada su R^1 i R^2 izborno uzeti zajedno tako da formiraju nesupstituiran i cikloheksil, i R^4 i R^5 su izborno uzeti zajedno tako da formiraju nesupstituiran i cikloheksil, tada A nije disupstituiran i 1-pirazolil ili nesupstituiran i fenil;
(iii) spoj nije izabran iz grupe koju čine:
(1) 6-(1H-imidazol-1-il)-N^2,N^4-bis(1-metiletil)-1,3,5-Triazin-2,4-diamin; ili
(2) N^2,N^4-bis(1-metilpropil)-6-fenil-1,3,5-Triazin-2,4-diamin;
i farmaceutski prihvatljiv nosač.

25. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 23 do 24, naznačena time što dodatno sadrži drugo terapeutsko sredstvo korisno u liječenju karcinoma.
26. Spoj, ili njegova farmaceutski prihvatljiva sol ili hidrat, ili farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1 do 9 ili 11 do 25 za upotrebu u postupku za liječenje karcinoma **naznačeno** prisustvom IDH1 mutacije, pri čemu IDH1 mutacija rezultira u novoj sposobnosti enzima da katalizira NADPH-zavisnu redukciju α-ketoglutarata u *R*(-)-2-hidroksiglutarat u pacijentu.
27. Spoj koji ima formulu Ig ili njegova farmaceutski prihvatljiva sol ili hidrat:



(Ig),

gdje

prsten A je izborno supstituiran 5-6 –člani monociklični aril ili monociklični heteroaril;

R^3 i R^6 su oba vodik ;

R^1 i R^4 su svaki nezavisno izabrani od C_1-C_4 alkila i C_1-C_4 haloalkila; i

R^2 i R^5 su svaki -(C_1-C_6 alkil); ili

R^1 i R^2 su izborno uzeti zajedno tako da formiraju izborno supstituiran monocikličan karbociklil; ili

R^4 i R^5 su izborno uzeti zajedno tako da formiraju izborno supstituiran monocikličan karbociklil;

gdje:

(i) prsten A nije izborno supstituiran triazolil, ili 3,5-dimetil-1H-pirazol-1-il,

(ii) kada su R^1 i R^2 izborno uzeti zajedno tako da formiraju nesupstituiran i cikloheksil, i R^4 i R^5 su izborno uzeti zajedno tako da formiraju nesupsupstituiran i cikloheksil, tada A nije disupstituiran 1-pirazolil ili nesupstituiran fenil;

(iii) spoj nije izabran iz grupe koju čine:

(1) 6-(1H-imidazol-1-il)-N^2,N^4-bis(1-metiletil)-1,3,5-Triazin-2,4-diamin; ili

(2) N^2,N^4-bis(1-metilpropil)-6-fenil-1,3,5-Triazin-2,4-diamin;

za upotrebu u postupku za liječenje karcinoma **naznačeno** prisustvom IDH1 mutacije, gdje IDH1 mutacija rezultira u novoj sposobnosti enzima da katalizira NADPH-zavisnu redukciju α-ketoglutarata u *R*(-)-2-hidroksiglutarat u pacijenta.

28. Spoj ili njegova farmaceutski prihvatljiva sol ili hidrat, ili farmaceutska kompozicija za upotrebu prema bilo kojem od patentnih zahtjeva 26 do 27, pri čemu IDH1 mutacija je IDH1 R132H ili R132C mutacija; i/ili pri čemu je karcinom izabran od glioma (glioblastoma), akutne mijelogene leukemije, sarkoma, melanoma, nesitnostaničnog karcinoma pluća (NSCLC), holangiokarcinoma, hondrosarkoma, mijelodisplastičnih sindroma (MDS), mijeloproliferativne neoplazme (MPN), karcinoma debelog crijeva ili angio-imunoblastičnog ne-Hodgkin-ovog limfoma (NHL) kod pacijenta, pri čemu, poželjno, karcinom je gliom.